首页> 外文期刊>European Journal of Pharmacology: An International Journal >Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
【24h】

Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.

机译:几种新化合物在小鼠PPQ拉伸试验中的非大麻CB1,非大麻CB2镇痛作用。

获取原文
获取原文并翻译 | 示例
           

摘要

The analgesic and anti-hyperalgesic effects of cannabinoid- and vanilloid-like compounds, plus the fatty acid amide hydrolase (FAAH) inhibitor Cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597), and acetaminophen, were evaluated in the phenyl-p-quinone (PPQ) pain model, using different routes of administration in combination with opioid and cannabinoid receptor antagonists. All the compounds tested produced analgesic effects. Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and (R)-(+)-arachidonyl-1'-hydroxy-2'-propylamide ((R)-methanandamide) were active by three routes of administration: i.p., s.c. and, p.o. Delta(9)-THC produced ED(50)s of 2.2 mg/kg (0.3-15.6) i.p., 9 mg/kg (4.3-18.9) s.c., and 6.4 mg/kg (5.5-7.6) p.o. Similarly, (R)-methanandamide yielded ED(50)s of 2.9 mg/kg (1-8) i.p., 11 mg/kg (7-17) s.c., and 11 mg/kg (0.9-134) p.o. N-vanillyl-arachidonyl-amide (arvanil) was active by two routes, producing ED(50)s of 4.7 mg/kg (3.0-7.4) s.c. and 0.06 mg/kg (0.02-0.2) i.p. Palmitoylethanolamide, URB597, and acetaminophen were active i.p., resulting in ED(50)s of 3.7 mg/kg (3.2-4.2), 22.9 mg/kg (11.1-47.2), and 160 mg/kg (63-405), respectively. None of the cannabinoid or opioid receptor antagonists tested blocked the compounds evaluated, with two exceptions: the antinociceptive effects of Delta(9)-THC and URB597 were completely blocked by SR141716A, a cannabinoid CB(1) receptor antagonist. Western immunoassays performed using three opioid receptor antibodies, a cannabinoid CB(1) receptor antibody and a transient receptor potential vanilloid type 1(TRPV(1)) receptor antibody, yielded no change in receptor protein levels after short-term arvanil, (R)-methanandamide or Delta(9)-THC administration. These data suggest that all the compounds tested, except Delta(9)-THC and URB597, produced analgesia via a non-cannabinoid CB(1), non-cannabinoid CB(2) pain pathway not yet identified.
机译:在大麻中评估了类大麻素和类香草素类化合物以及脂肪酸酰胺水解酶(FAAH)抑制剂环己基氨基甲酸3'-氨基甲酰基-联苯-3-基酯(URB597)和对乙酰氨基酚的镇痛和抗痛觉过敏作用。苯-对醌(PPQ)疼痛模型,使用不同的给药途径与阿片类药物和大麻素受体拮抗剂联合使用。所有测试的化合物均具有镇痛作用。 Delta(9)-四氢大麻酚(Delta(9)-THC)和(R)-(+)-花生四烯酸基1'-羟基-2'-丙酰胺((R)-甲烷酰胺)通过三种给药途径具有活性:ip ,sc还有Delta(9)-THC产生的ED(50)s.c.为2.2 mg / kg(0.3-15.6)s.c.,9 mg / kg(4.3-18.9)s.c.和6.4 mg / kg(5.5-7.6)s.c.同样,(R)-甲烷酰胺的ED(50)s.c. ip为2.9 mg / kg(1-8),皮下压力为11 mg / kg(7-17)和11 mg / kg(0.9-134)。 N-香草醛-花生四烯酸酰胺(arvanil)有两种活性,产生ED(50)s为4.7 mg / kg(3.0-7.4)s.c.和0.06 mg / kg(0.02-0.2)i.p.棕榈酰乙醇酰胺,URB597和对乙酰氨基酚是活性ip,导致ED(50)分别为3.7 mg / kg(3.2-4.2),22.9 mg / kg(11.1-47.2)和160 mg / kg(63-405)。 。测试的任何大麻素或阿片受体拮抗剂均未阻断所评估的化合物,但有两个例外:Delta(9)-THC和URB597的抗伤害作用已被大麻素CB(1)受体SR141716A完全阻断。使用三种阿片受体抗体,大麻素CB(1)受体抗体和瞬时受体电位类香草素1型(TRPV(1))受体抗体进行的Western免疫测定在短期阿凡尼尔使用后,受体蛋白水平没有变化,(R) -甲酰胺或Delta(9)-THC给药。这些数据表明,除Delta(9)-THC和URB597外,所有测试的化合物均通过非大麻类CB(1),非大麻类CB(2)疼痛途径产生镇痛作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号